IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in ...

IMUNON, Inc. has announced the initiation of a Phase 3 pivotal trial, OVATION 3, for its DNA-mediated immunotherapy candidate, IMNN-001, targeting newly diagnosed advanced ovarian cancer.

IMNN-001, an immunotherapy for advanced ovarian cancer, shows promising survival data, with a Phase 3 trial set for 2025. IMUNON, Inc. reported that its DNA-mediated immunotherapy, IMNN-001 ...

Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose Results from OVATION 2 Study continue to validate ...

Briefly, the results showed that in the intent-to-treat (ITT) population, treatment with IMNN-001 resulted in an 11.1 month increase in overall survival (OS) with a hazard ratio (HR) of 0.74.

“The Phase 2 OVATION 2 study data are highly encouraging, demonstrating that IMNN-001 is the first immunotherapy to achieve a clinically effective response in ovarian cancer, including benefits ...

Results demonstrated a 20% increase in IL-12 levels in women treated with IMNN-001 (100 mg/m 2 administered intraperitoneally weekly) plus standard-of-care (SoC) neoadjuvant and adjuvant ...